NCT01577251 The Radiation Oncology Registry and Biosample Repository
| NCT ID | NCT01577251 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Neoplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2008-06 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,000 participants in total. It began in 2008-06 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to establish a registry and biosample repository (defined as blood, urine, and tumor specimens) in patients with a cancer and/or benign tumor diagnosis undergoing radiotherapy.
Eligibility Criteria
* Anyone age 18 and above with a cancer and/or benign tumor diagnosis undergoing radiotherapy * Able to sign consent
Contact & Investigator
Project Manager
✉ radonccru@pennmedicine.upenn.eduJay Dorsey, MD, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT01577251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01577251 currently recruiting?
Yes, NCT01577251 is actively recruiting participants. Contact the research team at radonccru@pennmedicine.upenn.edu for enrollment information.
Where is the NCT01577251 trial being conducted?
This trial is being conducted at Moorestown, United States, Voorhees Township, United States, Lancaster, United States, Philadelphia, United States.
Who is sponsoring the NCT01577251 clinical trial?
NCT01577251 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Jay Dorsey, MD, PhD at University of Pennsylvania. The trial plans to enroll 8,000 participants.